help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swartz, S. L.
Right arrow Articles by Moore, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swartz, S. L.
Right arrow Articles by Moore, T. J.

Journal of Clinical Endocrinology & Metabolism, Vol 50, 1071-1074, Copyright © 1980 by Endocrine Society


ARTICLES

Primacy of the renin-angiotensin system in mediating the aldosterone response to sodium restriction

SL Swartz, GH Williams, NK Hollenberg, RG Dluhy and TJ Moore

The primacy of angiotensin II as the mediator of the adrenal's response to sodium restriction is controversial. We administered the oral converting enzyme inhibitor, captopril (SQ 14225), to test whether reduction of angiotension II generation for 26 h in sodium-restricted subjects would lower plasma aldosterone levels to values observed in subjects on a high sodium intake. Accordingly, plasma angiotensin II and aldosterone levels were measured in nine recumbent normal subjects on high (200 meq) and low (10 meq) sodium intakes and low sodium intake with captopril (12.5--25 mg four times a day for 26 h). Captopril reduced the sodium-restricted angiotensin II levels from 31 +/- 6 to 13 +/- 2 pg/ml, which was indistinguishable from that measured on the high sodium intake (11 +/- 2 pg/ml). Concomitantly, aldosterone levels were reduced from 25 +/- 4 to 7 +/- 1 ng/dl, which was similar to the high sodium value (8 +/- 1 ng/dl). There were no significant changes in serum sodium, cortisol, or potassium at the three sampling times. Thus, the complete suppression of the sodium-restricted levels of both angiotensin II and aldosterone into the high sodium range by captopril provides strong support for the hypothesis that the renin-angiotensin system is the prime mediator of the adrenal's response to sodium restriction.


This article has been cited by other articles:


Home page
EndocrinologyHome page
Z. Wu, W. Zheng, and K. Sandberg
Estrogen Regulates Adrenal Angiotensin Type 1 Receptors by Modulating Adrenal Angiotensin Levels
Endocrinology, April 1, 2003; 144(4): 1350 - 1356.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. N. IBRAHIM and T. H. HOSTETTER
Role of Dietary Potassium in the Hyperaldosteronism and Hypertension of the Remnant Kidney Model
J. Am. Soc. Nephrol., April 1, 2000; 11(4): 625 - 631.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Ehrhart-Bornstein, J. P. Hinson, S. R. Bornstein, W. A. Scherbaum, and G. P. Vinson
Intraadrenal Interactions in the Regulation of Adrenocortical Steroidogenesis
Endocr. Rev., April 1, 1998; 19(2): 101 - 143.
[Abstract] [Full Text]


Home page
HypertensionHome page
S. K. Gandhi, J. Gainer, D. King, and N. J. Brown
Gender Affects Renal Vasoconstrictor Response to Ang I and Ang II
Hypertension, January 1, 1998; 31(1): 90 - 96.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. K. Gandhi, D. H. Ryder, and N. J. Brown
Losartan Blocks Aldosterone and Renal Vascular Responses to Angiotensin II in Humans
Hypertension, December 1, 1996; 28(6): 961 - 966.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society